KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (ONC) EPS (Weighted Average and Diluted) (2016 - 2025)

BeOne Medicines (ONC) has disclosed EPS (Weighted Average and Diluted) for 10 consecutive years, with $0.04 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 140.0% to $0.04 in Q4 2025 year-over-year; TTM through Dec 2025 was $0.19, a 140.43% increase, with the full-year FY2025 number at $0.19, up 140.43% from a year prior.
  • EPS (Weighted Average and Diluted) was $0.04 for Q4 2025 at BeOne Medicines, down from $0.09 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.15 in Q3 2023 to a low of -$0.5 in Q4 2021.
  • A 5-year average of -$0.18 and a median of -$0.22 in 2023 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): crashed 760.0% in 2022, then surged 200.0% in 2025.
  • BeOne Medicines' EPS (Weighted Average and Diluted) stood at -$0.5 in 2021, then soared by 34.0% to -$0.33 in 2022, then increased by 21.21% to -$0.26 in 2023, then soared by 61.54% to -$0.1 in 2024, then skyrocketed by 140.0% to $0.04 in 2025.
  • Per Business Quant, the three most recent readings for ONC's EPS (Weighted Average and Diluted) are $0.04 (Q4 2025), $0.09 (Q3 2025), and $0.06 (Q2 2025).